OverviewSuggest Edit

Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

TypePublic
Founded2002
HQNew York, US
Websiteintracellulartherapies.com

Locations

Intra-Cellular Therapies is headquartered in
New York, United States

Location Map

Latest Updates

Employees (est.) (Feb 2020)330(+353%)
Revenue (FY, 2019)$60.6 K(-75%)
Share Price (Oct 2020)$26.3 (-1%)
Cybersecurity ratingBMore

Key People/Management at Intra-Cellular Therapies

Sharon Mates

Sharon Mates

Founder, Chairman & Chief Executive Officer
Andrew Satlin

Andrew Satlin

Executive Vice President and Chief Medical Officer
Mark Neumann

Mark Neumann

Executive Vice President, Chief Commercial Officer
Richard Lerner

Richard Lerner

Director
Christopher Alafi

Christopher Alafi

Director
Michael I. Halstead

Michael I. Halstead

Executive Vice President and General Counsel
Show more

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
430 E 29th St #900
Show all (1)

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $60.61 k in FY, 2019
USD

Revenue (Q2, 2020)

1.9m

Net income (Q2, 2020)

(63.7m)

EBIT (Q2, 2020)

(64.9m)

Market capitalization (16-Oct-2020)

2.1b

Closing stock price (16-Oct-2020)

26.3

Cash (30-Jun-2020)

129.3m

EV

2.0b
Intra-Cellular Therapies's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.7m577.3k91.4k330.7k245.8k60.6k

Revenue growth, %

(79%)(84%)262%

General and administrative expense

6.0m10.3m18.2m24.8m23.7m30.1m64.9m

R&D expense

23.0m21.2m87.7m93.8m79.4m132.2m89.1m
Quarterly
USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k228.4k4.4k95.3k114.7k30.8k1.1m1.9m

Cost of goods sold

69.0k

Gross profit

1.0m

Gross profit Margin, %

94%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

35.2m61.3m47.2m48.6m37.8m54.9m107.6m

Accounts Receivable

336.3k51.6k30.7k94.3k

Prepaid Expenses

762.2k1.3m8.0m4.9m7.9m6.3m

Inventories

4.0m
Quarterly
USDQ1, 2014Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.044.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m69.8m64.1m91.8m102.2m179.6m129.3m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k98.2k1.3k68.2k61.9k6.3k1.4m2.4m

Prepaid Expenses

806.3k585.1k493.4k1.4m1.3m8.6m1.5m6.8m4.0m4.0m3.8m6.1m5.3m6.1m5.9m7.3m8.3m3.0m4.0m7.9m4.7m

Inventories

1.4m2.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)(155.1m)(147.7m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k368.7k477.1k

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m7.8m(6.5m)

Cash From Operating Activities

(22.6m)(22.8m)(102.3m)(91.3m)(80.5m)(118.2m)(128.0m)
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Online and Social Media Presence

Embed Graph

Intra-Cellular Therapies News and Updates

Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Dr. Suresh Durgam to the position of C…

Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and …

Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference

NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and …

Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics?

NEW YORK, Sept. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, VBLT, ITCI, AGEN, and CODX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Intra-Cellular Therapies, AMC Entertainment, Vaxart Inc, Norwegian Cruise Line, or Southwest Airlines?

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, AMC, VXRT, NCLH, and LUV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended Jun…
Show more

Intra-Cellular Therapies Blogs

Intra-Cellular Therapies Frequently Asked Questions

  • When was Intra-Cellular Therapies founded?

    Intra-Cellular Therapies was founded in 2002.

  • Who are Intra-Cellular Therapies key executives?

    Intra-Cellular Therapies's key executives are Sharon Mates, Andrew Satlin and Mark Neumann.

  • How many employees does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 330 employees.

  • What is Intra-Cellular Therapies revenue?

    Latest Intra-Cellular Therapies annual revenue is $60.6 k.

  • What is Intra-Cellular Therapies revenue per employee?

    Latest Intra-Cellular Therapies revenue per employee is $184 .

  • Who are Intra-Cellular Therapies competitors?

    Competitors of Intra-Cellular Therapies include PhaseBio Pharmaceuticals, Hancock Jaffe and Microbion.

  • Where is Intra-Cellular Therapies headquarters?

    Intra-Cellular Therapies headquarters is located at 430 E 29th St #900, New York.

  • Where are Intra-Cellular Therapies offices?

    Intra-Cellular Therapies has an office in New York.

  • How many offices does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 1 office.